Oncology

antibody antibody-drug conjugate antibody drug conjugate ADC
Biotech

Boehringer digs in on ADCs with $991M AimedBio licensing accord

After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well.
Fraiser Kansteiner Oct 15, 2025 10:05am
Graphic images of different entities adding money to a pile

Tubulis touts $361M series C as next-gen ADC data drop nears

Oct 15, 2025 5:01am
AZ

Turbine looks to turbocharge AstraZeneca's ADC discovery

Oct 9, 2025 6:00am
Anthony Letai

Dana-Farber oncologist Anthony Letai tapped to direct NCI

Sep 30, 2025 5:50am
viking ship long boat chase race water sunset

BioLineRx forges joint cancer venture with Norwegian biotech

Sep 29, 2025 11:22am
reducing people on team

ArsenalBio halves staff amid reorganization efforts

Sep 17, 2025 4:55pm
More News

Servier hands Ideaya $210M upfront for ex-US rights to PKC asset

Sep 2, 2025 3:02pm

Allogene reports patient death tied to mAb in CAR-T pivotal trial

Aug 1, 2025 8:30am

Roche's Flatiron triples cancer network across 3 countries

Jul 23, 2025 12:20pm

Repare finds suitor for PKMYT1 inhibitor in partner Debiopharm

Jul 16, 2025 5:38am